EyePoint Pharmaceuticals (EYPT) Prices 9.1M Share Common Offering at $11/Sh

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds of the offering to the Company are expected to be $100.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 1,365,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions.

Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.

EyePoint intends to use the net proceeds from the offering for the advancement of EYP-1901 for wet AMD, for pipeline and commercial programs, and for general corporate purposes.

You May Also Be Interested In

• SOPHiA Genetics closes $57.5M public offering at $4.75 per share
• Sharplink prices $75M stock offering at 41% premium to last close
• UnitedHealth Group (UNH) PT Lowered to $197 at TD Cowen